5 completed, 3 unknown. 6 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Unknown 3 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow rifamycin SV: new trials by email Literature Review of rifamycin SV trials Research Report on rifamycin SV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years Rifamycin SV-MMX, Placebo - Traveler's Diarrhea | Phase 2 | Unknown | RedHill Biopharma Limited | 142 | 2024-06-01 | 2023-01-27 |
| Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years Rifamycin SV MMX, Placebo to Rifamycin SV-MMX - Traveler's Diarrhea | Phase 2 | Unknown | RedHill Biopharma Limited | 142 | 2024-01-01 | 2023-01-27 |
| Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) AEMCOLO (Rifamycin SV MMX) - Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease | Phase 2 | Unknown | Bradley Connor | 30 | 2020-06-30 | 2022-05-05 |
| Rifamycin in Minimal Hepatic Encephalopathy Rifamycin SV MMX, Placebo - Hepatic Encephalopathy, Cirrhosis, Liver | Phase 2 | Completed | Hunter Holmes Mcguire Veteran Affairs Medical Center | 30 | 2019-09-01 | 2023-09-21 |
| Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D Rifamycin SV 600mg t.i.d., Rifamycin SV b.i.d. + Placebo, Placebo t.i.d. - Diarrhea-predominant Irritable Bowel Syndrome | Phase 2 | Completed | Cosmo Technologies Ltd | 279 | 2017-12-18 | 2021-01-08 |
| Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women Rifapentine (RPT), Isoniazid (INH), Pyridoxine (vitamin B6) - Tuberculosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2017-03-13 | 2021-11-04 |
| Immune Activation and Drug Absorption in HIV-Infected Patients Rifampicin 600 mg - HIV Infection | Not applicable | Completed | Drexel University | 7 | 2014-06-01 | 2017-03-03 |
| Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions Rifampicin, sulforaphane plus rifampicin, sulforaphane alone - Adverse Drug Interactions | Phase 1 | Completed | University of Washington | 29 | 2008-03-01 | 2019-09-06 |
Gastrointestinal Diseases (1) · HIV Infections (1) · Hepatic Encephalopathy (1) · Liver Cirrhosis (1) · Tuberculosis (1)
RedHill Biopharma Limited (2) · Bradley Connor (1) · Cosmo Technologies Ltd (1) · Drexel University (1) · Hunter Holmes Mcguire Veteran Affairs Medical Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Washington (1)
United States (4) · Belgium (1) · Germany (1) · Haiti (1) · Italy (1) · Kenya (1) · Malawi (1) · Spain (1) · Thailand (1) · Zimbabwe (1)
June Almenoff, MD, PhD (2) · Christopher Vinnard, MD (1) · David L Eaton, PhD (1) · Jyoti S. Mathad, MD, MSc (1)